KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Income from Continuing Operations (2016 - 2026)

Pacira BioSciences has reported Income from Continuing Operations over the past 17 years, most recently at 2916000.0 for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 39.4% year-over-year to 2916000.0; the TTM value through Mar 2026 reached 5138000.0, up 104.95%, while the annual FY2025 figure was 7034000.0, 107.07% up from the prior year.
  • Income from Continuing Operations for Q1 2026 was 2916000.0 at Pacira BioSciences, up from 1637000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 25763000.0 in Q2 2023 and troughed at 143466000.0 in Q3 2024.
  • A 5-year average of 1867411.76 and a median of 5432000.0 in 2025 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: soared 1666.81% in 2023 and later crashed 1421.29% in 2024.
  • Year by year, Income from Continuing Operations stood at 10102000.0 in 2022, then surged by 346.19% to 24870000.0 in 2023, then tumbled by 35.5% to 16041000.0 in 2024, then tumbled by 89.79% to 1637000.0 in 2025, then surged by 78.13% to 2916000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for PCRX at 2916000.0 in Q1 2026, 1637000.0 in Q4 2025, and 5432000.0 in Q3 2025.